Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1975 1
1990 1
1991 1
1992 1
1993 1
1995 1
1996 3
1997 1
1998 2
1999 2
2000 3
2001 3
2002 1
2003 2
2005 1
2006 5
2007 8
2008 8
2009 8
2010 5
2011 5
2012 5
2013 7
2014 13
2015 18
2016 17
2017 16
2018 22
2019 21
2020 36
2021 36
2022 38
2023 47
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
A novel antibiotic class targeting the lipopolysaccharide transporter.
Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, Adam JM, Alanine A, Amrein KE, Baidin V, Bieniossek C, Bissantz C, Boess F, Cantrill C, Clairfeuille T, Dey F, Di Giorgio P, du Castel P, Dylus D, Dzygiel P, Felici A, García-Alcalde F, Haldimann A, Leipner M, Leyn S, Louvel S, Misson P, Osterman A, Pahil K, Rigo S, Schäublin A, Scharf S, Schmitz P, Stoll T, Trauner A, Zoffmann S, Kahne D, Young JAT, Lobritz MA, Bradley KA. Zampaloni C, et al. Nature. 2024 Jan;625(7995):566-571. doi: 10.1038/s41586-023-06873-0. Epub 2024 Jan 3. Nature. 2024. PMID: 38172634 Free PMC article.
Determinants of telomere length across human tissues.
Demanelis K, Jasmine F, Chen LS, Chernoff M, Tong L, Delgado D, Zhang C, Shinkle J, Sabarinathan M, Lin H, Ramirez E, Oliva M, Kim-Hellmuth S, Stranger BE, Lai TP, Aviv A, Ardlie KG, Aguet F, Ahsan H; GTEx Consortium; Doherty JA, Kibriya MG, Pierce BL. Demanelis K, et al. Science. 2020 Sep 11;369(6509):eaaz6876. doi: 10.1126/science.aaz6876. Science. 2020. PMID: 32913074 Free PMC article.
Violences et thérapeutiques 1/2.
Roynard P, Castel C, Lebain P, Roupie É, Saint-Lorant G. Roynard P, et al. Rev Infirm. 2016 Nov;65(225):45-46. doi: 10.1016/j.revinf.2016.08.033. Rev Infirm. 2016. PMID: 27968973 French. No abstract available.
Violences et thérapeutiques 2/2.
Roynard P, Castel C, Lebain P, Roupie É, Saint-Lorant G. Roynard P, et al. Rev Infirm. 2017 Jan;66(227):45-46. doi: 10.1016/j.revinf.2016.11.019. Rev Infirm. 2017. PMID: 28048997 French. No abstract available.
Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design.
Monti G, Galbiati C, Toffoletto F, Calabrò MG, Colombo S, Ferrara B, Giardina G, Lembo R, Marzaroli M, Moizo E, Mucci M, Pasculli N, Plumari VP, Scandroglio AM, Tozzi M, Momesso E, Boffa N, Lobreglio R, Montrucchio G, Guarracino F, Benedetto U, Biondi-Zoccai G, D'Ascenzo F, D'Andrea N, Paternoster G, Ananiadou S, Ballestra M, De Sio A, Pota V, Cotoia A, Della Selva A, Bruni A, Iapichino G, Bradić N, Corradi F, Gemma M, Nogtev P, Petrova M, Agrò FE, Cabrini L, Forfori F, Likhvantsev V, Bove T, Finco G, Landoni G, Zangrillo A; Collaborators. Monti G, et al. Contemp Clin Trials. 2021 May;104:106346. doi: 10.1016/j.cct.2021.106346. Epub 2021 Mar 6. Contemp Clin Trials. 2021. PMID: 33684595 Clinical Trial.
INTERVENTIONS: 600 ICU patients with sepsis or septic shock, needing by clinical judgment antibiotic therapy with meropenem, will be randomized to receive a continuous infusion of meropenem 3 g/24 h or an equal dose divided into three daily boluses (i.e. 1g q8h). ...
INTERVENTIONS: 600 ICU patients with sepsis or septic shock, needing by clinical judgment antibiotic therapy with meropenem, will be randomi …
Lessons from the past.
Basile F, Calise F. Basile F, et al. Updates Surg. 2020 Sep;72(3):563. doi: 10.1007/s13304-020-00875-7. Updates Surg. 2020. PMID: 32880869 Free PMC article. No abstract available.
Evolution of class A G-protein-coupled receptors: implications for molecular modeling.
Chabbert M, Castel H, Pele J, Deville J, Legendre R, Rodien P. Chabbert M, et al. Curr Med Chem. 2012;19(8):1110-8. doi: 10.2174/092986712799320600. Curr Med Chem. 2012. PMID: 22300045 Free article. Review.
Class A or rhodopsin-like G-protein-coupled receptors (GPCRs) constitute the largest transmembrane receptor family of the human genome. ...
Class A or rhodopsin-like G-protein-coupled receptors (GPCRs) constitute the largest transmembrane receptor family of the human genom …
The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.
Castel H, Desrues L, Joubert JE, Tonon MC, Prézeau L, Chabbert M, Morin F, Gandolfo P. Castel H, et al. Front Endocrinol (Lausanne). 2017 Apr 25;8:76. doi: 10.3389/fendo.2017.00076. eCollection 2017. Front Endocrinol (Lausanne). 2017. PMID: 28487672 Free PMC article. Review.
Thus, it turns out that the actions of the urotensin II (UII)/G protein-coupled receptor UT system in animal models are currently not predictive enough in regard to their effects in human clinical trials and that UII analogs, established to target UT, were not as beneficia …
Thus, it turns out that the actions of the urotensin II (UII)/G protein-coupled receptor UT system in animal models are currently not …
312 results